INM · InMed Pharmaceuticals Inc.
$1.46
-0.01 (-0.68%)
At close · Aug 17
Going-concern doubt
— flagged May 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. management has determined that the Company's liquidity condition raises substantial doubt about the Company's ability to continue as a going concern, which is considered to be for a period of one year from the issuance of these financial statements.”View the 10-Q filed May 6, 2026
Market Cap
$4.84M
Shares
3.31M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.47
Open$1.45
Day$1.44–1.50
52W close$0.62–2.46
Avg vol 30d1.9M
Short int83K · 2.5% float · 1.0d
Short vol60%
Last earningsJun 30, 2021
DataNov 2024–Aug 2026
Filing10-Q · May 6
Raw chart and full-history price indicators begin at the captured split on Nov 14, 2024; bars on opposite sides are not compared.
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Very Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+22%
above
Price vs 50-day avg
−5%
below
RSI (14)
47
neutral
MACD trend
Negative
52-week position
46%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−3%
trailing
6-month return
+73%
trailing
YTD return
+39%
this year
Relative strength
+59%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+122% holders QoQ · +13 funds added
Insider flow
Accumulating
Net +$435.1K over 90 days · 0% sells
Short interest
Falling
2.51% of float · ▼ -30.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
20 holders — near 3-yr high, broad support
Squeeze score
48
elevated · 0–100
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
35%
expanding
EPS growth
+58%
Y/Y
Free cash flow
$-7.8M
Balance sheet
$10.7M
net cash
Quant / Vol
risk profile
Volatility
154%
annualized · 1-yr
Max drawdown
−75%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+22%
Bullish
Price vs 50-day avg
−5%
Bearish
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
46%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
No cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+122% holders QoQ · +13 funds added
Insider flow
Accumulating
Net +$435.1K over 90 days · 0% sells
Short interest
Falling
2.51% of float · ▼ -30.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
20 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 46%
Range high $2
vs 200-day avg +22%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INM
this stock
InMed Pharmaceuticals Inc.
|
$4.84M | +38.7% | +7.5% | — | 2.5% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$48.51B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
20
- % held
- 81.4%
- Net QoQ
- +2.4M sh
- Top holder
- ADAR1 Capital Management,…
Held
Float
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Nov 14, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INM | +0.0% | -3.3% | +72.9% | +0.0% | +38.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -0.4% | -7.7% | +59.2% | -3.9% | +24.8% |